XML 28 R11.htm IDEA: XBRL DOCUMENT v3.25.3
Marketable Securities
9 Months Ended
Oct. 31, 2025
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities Marketable Securities
The following is a summary of available-for-sale marketable securities, excluding those securities classified within cash and cash equivalents on the condensed consolidated balance sheets:
October 31, 2025
(in thousands)Amortized CostUnrealized GainsUnrealized LossesFair value
Corporate bonds$114,760 $55 $(35)$114,780 
Municipal bonds1,570 — — 1,570 
U.S. government and agency securities104,853 29 (40)104,842 
Certificates of deposit26,055 20 (1)26,074 
Commercial paper43,499 (15)43,488 
Marketable securities$290,737 $108 $(91)$290,754 
January 31, 2025
(in thousands)Amortized CostUnrealized GainsUnrealized LossesFair value
Corporate bonds$106,632 $48 $(26)$106,654 
Municipal bonds12,752 — (7)12,745 
U.S. government and agency securities120,032 28 (52)120,008 
Certificates of deposit34,584 27 — 34,611 
Commercial paper64,180 16 (25)64,171 
Marketable securities$338,180 $119 $(110)$338,189 
As of October 31, 2025 and January 31, 2025, the maturities of available-for-sale marketable securities did not exceed 12 months. Interest income from cash and cash equivalents and marketable securities was $4.6 million and $15.5 million for the three and nine months ended October 31, 2025, respectively, and $5.6 million and $20.9 million for the three and nine months ended October 31, 2024, respectively.
There were 34 and 40 debt securities in an unrealized loss position as of October 31, 2025 and January 31, 2025, respectively. The estimated fair value of these debt securities, for which an allowance for credit losses has not been recorded, was $94.0 million and $140.0 million as of October 31, 2025 and January 31, 2025, respectively. There were no expected credit losses recorded against the Company’s investment securities as of October 31, 2025 and January 31, 2025.
Unrealized losses on the Company’s debt securities are not considered to be credit-related based upon an analysis that considered the extent to which the fair value is less than the amortized basis of a security, adverse conditions specifically related to the security, changes to credit rating of the instrument subsequent to Company purchase, and the strength of the underlying collateral, if any.
Refer to Note 5, Fair Value Measurements, for information about the Company’s fair value hierarchy for short-term marketable securities.